company background image
SGMO

Sangamo Therapeutics NasdaqGS:SGMO Stock Report

Last Price

US$4.31

Market Cap

US$632.2m

7D

20.4%

1Y

-64.1%

Updated

26 Jun, 2022

Data

Company Financials +
SGMO fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SGMO Stock Overview

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation.

Sangamo Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Sangamo Therapeutics
Historical stock prices
Current Share PriceUS$4.31
52 Week HighUS$12.83
52 Week LowUS$3.12
Beta1.62
1 Month Change21.75%
3 Month Change-25.04%
1 Year Change-64.14%
3 Year Change-59.98%
5 Year Change-51.02%
Change since IPO-71.39%

Recent News & Updates

May 08
Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

One thing we could say about the analysts on Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) - they aren't optimistic...

Shareholder Returns

SGMOUS BiotechsUS Market
7D20.4%10.3%6.6%
1Y-64.1%-24.3%-18.4%

Return vs Industry: SGMO underperformed the US Biotechs industry which returned -24.4% over the past year.

Return vs Market: SGMO underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is SGMO's price volatile compared to industry and market?
SGMO volatility
SGMO Average Weekly Movement12.0%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: SGMO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: SGMO's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995431Sandy Macraehttps://www.sangamo.com

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease.

Sangamo Therapeutics Fundamentals Summary

How do Sangamo Therapeutics's earnings and revenue compare to its market cap?
SGMO fundamental statistics
Market CapUS$632.22m
Earnings (TTM)-US$176.33m
Revenue (TTM)US$112.65m

5.6x

P/S Ratio

-3.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SGMO income statement (TTM)
RevenueUS$112.65m
Cost of RevenueUS$232.97m
Gross Profit-US$120.32m
Other ExpensesUS$56.01m
Earnings-US$176.33m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.20
Gross Margin-106.80%
Net Profit Margin-156.53%
Debt/Equity Ratio0%

How did SGMO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SGMO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SGMO?

Other financial metrics that can be useful for relative valuation.

SGMO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.4x
Enterprise Value/EBITDA-1.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SGMO's PS Ratio compare to its peers?

SGMO PS Ratio vs Peers
The above table shows the PS ratio for SGMO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average114.7x

Price-To-Sales vs Peers: SGMO is good value based on its Price-To-Sales Ratio (5.6x) compared to the peer average (114.7x).


Price to Earnings Ratio vs Industry

How does SGMO's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: SGMO is good value based on its Price-To-Sales Ratio (5.6x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is SGMO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SGMO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.6x
Fair PS Ratio1.3x

Price-To-Sales vs Fair Ratio: SGMO is expensive based on its Price-To-Sales Ratio (5.6x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).


Share Price vs Fair Value

What is the Fair Price of SGMO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SGMO ($4.31) is trading below our estimate of fair value ($142.02)

Significantly Below Fair Value: SGMO is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SGMO's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Sangamo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


14.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SGMO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SGMO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SGMO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SGMO's revenue (32.5% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: SGMO's revenue (32.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SGMO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Sangamo Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-24.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SGMO is currently unprofitable.

Growing Profit Margin: SGMO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SGMO is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.

Accelerating Growth: Unable to compare SGMO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SGMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: SGMO has a negative Return on Equity (-52.71%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Sangamo Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SGMO's short term assets ($340.1M) exceed its short term liabilities ($118.5M).

Long Term Liabilities: SGMO's short term assets ($340.1M) exceed its long term liabilities ($201.3M).


Debt to Equity History and Analysis

Debt Level: SGMO is debt free.

Reducing Debt: SGMO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SGMO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SGMO has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 15.6% each year.


Discover healthy companies

Dividend

What is Sangamo Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SGMO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SGMO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SGMO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SGMO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SGMO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Sandy Macrae (58 yo)

6yrs

Tenure

US$4,735,817

Compensation

Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...


CEO Compensation Analysis

Compensation vs Market: Sandy's total compensation ($USD4.74M) is about average for companies of similar size in the US market ($USD4.05M).

Compensation vs Earnings: Sandy's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: SGMO's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: SGMO's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SGMO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sangamo Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sangamo Therapeutics, Inc.
  • Ticker: SGMO
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$632.222m
  • Shares outstanding: 146.69m
  • Website: https://www.sangamo.com

Number of Employees


Location

  • Sangamo Therapeutics, Inc.
  • Brisbane
  • California
  • 94005
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.